Advancing Care in Cholestatic and Autoimmune Liver Disease
A clinician-led Special Interest Group dedicated to evidence-based diagnosis, management, and research in cholestatic and autoimmune liver diseases for practising physicians.
Office bearers
Dr. Bilal Bobat
Chair
MBChB, FCP, Cert Gastroenterology · Transplant Hepatology / Gastroenterology
Dr. Kenan Moral
Vice-Chair
Lokman Hekim University · Liver Transplant
Prof. Sanjaya Satapathy
Secretary
MBBS, MD, DM, MS, FAASLD, FACG, AGAF, FASGE · Transplant Hepatology
Why this SIG, right now
Cholestatic and autoimmune liver diseases span a complex and evolving landscape. Practising clinicians need timely, evidence-grounded resources to navigate diagnosis, therapeutics, and long-term management with confidence.
The therapeutic options available for conditions such as primary biliary cholangitis, primary sclerosing cholangitis, and autoimmune hepatitis have expanded considerably in recent years. Staying current with emerging agents and integrating them appropriately into practice requires ongoing engagement with the evidence base.
Delayed diagnosis remains a significant contributor to disease progression and adverse outcomes in this patient population. Recognising early clinical, biochemical, and histological patterns enables timely intervention and can meaningfully alter the disease course.
Translating findings from mechanistic studies and clinical trials into day-to-day patient management requires active interpretation and peer discussion. This group provides a structured forum for clinicians to engage with emerging data and apply it within the realities of their practice.
Join Cholestatic & Autoimmune Liver Disease to read and participate in the discussion board.
Sign InChair's Note
Cholestatic and autoimmune liver diseases remain underdiagnosed and undertreated, with real consequences for patients who present years into their disease course. This group exists to close that gap by connecting clinicians with current evidence, emerging therapies, and a community of peers committed to raising the standard of care.
Cholestatic and autoimmune liver diseases represent a unique and complex spectrum within hepatology.
Conditions such as:
are often chronic, progressive, and require long-term, nuanced management.
Yet, these diseases are frequently:
At the same time, the field is rapidly evolving:
Clinicians are often faced with key questions:
The Cholestatic & Autoimmune Liver Disease Special Interest Group (SIG) was created to address these challenges.
Each session focuses on practical, case-based learning—translating specialized knowledge into real-world clinical decision-making.
This SIG brings together hepatologists, gastroenterologists, pathologists, and researchers to create a precision-focused, expertise-driven learning environment.
Because in these diseases, early diagnosis and targeted therapy can significantly alter the disease trajectory.
Dr. Bilal Bobat, MBChB, FCP, Cert Gastroenterology
Chair